Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir combinations in HIV-1 adult population: A systematic review and meta-analysis

被引：0
|
作者：
Biju, Anto Amith J. [1 ]
Shaju, Aina [2 ]
Mudigubba, Manoj Kumar [3 ]
机构：
[1] Ramaiah Univ Appl Sci, Dept Pharm Practice, Bangalore, Karnataka, India
[2] MS Ramaiah Univ Appl Sci, Fac Pharm, Bangalore, Karnataka, India
[3] Ramaiah Univ Appl Sci, Dept Pharm Practice, Fac Pharm, Bangalore, Karnataka, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
710
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [1] Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Emma D. Deeks
    [J]. Drugs, 2018, 78 : 1817 - 1828
  • [2] Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Deeks, Emma D.
    [J]. DRUGS, 2018, 78 (17) : 1817 - 1828
  • [3] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
    Acosta, R.
    Andreatta, K.
    D'Antoni, M.
    Collins, S.
    Martin, H.
    White, K.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
  • [4] Restarting bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: A pooled analysis of studies in people with HIV-1
    Pozniak, A.
    Orkin, C.
    Maggiolo, F.
    Yazdanpanah, Y.
    Baumgarten, A.
    Mounzer, K.
    D'Antoni, M. L.
    Huang, H.
    Liu, H.
    Andreatta, K.
    VanderVeen, L.
    Callebaut, C.
    Hindman, J. T.
    Martin, H.
    Arribas, J. R.
    [J]. HIV MEDICINE, 2023, 24 : 195 - 196
  • [5] Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
    Emma D. Deeks
    [J]. Drugs, 2019, 79 : 687 - 687
  • [6] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [7] Efficacy and safety of fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV-1: A systematic review and meta-analysis
    Wang, W.
    Zhao, S.
    Li, S.
    Huang, X.
    [J]. HIV MEDICINE, 2023, 24 : 214 - 215
  • [8] Pharmacokinetics, safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV
    Zhang, H.
    Martin, H.
    Lin, L.
    Davis, M.
    Huang, H.
    Xiao, D.
    Arora, P.
    Avihingsanon, A.
    Koenig, E.
    Palaparthy, R.
    Girish, S.
    Marathe, D.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [9] HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    D'Antoni, Michelle L.
    Andreatta, Kristen
    Chang, Silvia
    Cox, Stephanie
    Hindman, Jason T.
    Avihingsanon, Anchalee
    Martin, Hal
    Vanderveen, Laurie A.
    Callebaut, Christian
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (04) : 380 - 384
  • [10] Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
    I-Wen Chen
    Hsin-Yun Sun
    Chien-Ching Hung
    [J]. Infectious Diseases and Therapy, 2021, 10 : 1331 - 1346
12345